Kun Pharmaceutical Group ranks among the top 100 Chinese medicine enterprises TOP17.

Recently, the 2020 National Pharmacy Week and china's top 100 pharmaceutical industry annual meeting - China's pharmaceutical Internet economy annual meeting in Kunming Yun'an will be opened.
at the 2019 China Pharmaceutical Industry Top 100 Launch Ceremony with the theme of "Percentage Quality and Percent Care", Kun Pharmaceutical Group was ranked 17th in the TOP100 list of Chinese traditional medicine enterprises in 2019.
, President of Kun Pharmaceutical Group, was invited to open the conference with a large number of pharmaceutical entrepreneurs and political guests.
, said crises and challenges have coexisted with changes in the pharmaceutical industry over the past few years.
restructuring and ecological functional disruption of the industry, enterprises need to focus on integrating more resources, seize the opportunities of the industry, to meet the next take-off.
stags can be deer by deer, but there is no reason for wood to seek fish.
as a pharmaceutical enterprise for nearly 70 years, Kun medicine originated from nature and from plant medicine.
In the past few years, Kun Pharmaceutical Group has focused on transformation, firmly implementing the "prescription re-retailing, prescription and retailing" two-wheel drive strategy, through the company's core products, the company's blood plug," gradually into the retail market.
, research and development innovation is the gene of Kun medicine, but also kun medicine in the future to continue to build the core capacity.
Zhongxianggang said that the next step, Kun medicine in the retail market to continue to make efforts to become a brand enterprise in the field of Chinese medicine.
With the help of power health consumption and innovative research and development, we work with industry partners to build a slow disease management ecosystem to increase the flow, profit, increment and energy for partners in this era of openness and inclusion, game and cooperation.
the future, Kun Pharmaceutical Group will always focus on the health industry and slow disease management, deeply cultivate innovative research and development path, so that quality, research and development, professional efforts to reach consumers, and industry partners to create a new future of Chinese medicine.
.